Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19743718 | 0.84 | GPR35 (0.49) | GPR35KDM4EMAOBCSNK2A2CSNK2B | |
| SCHEMBL19744171 | 0.83 | GPR35 (0.48) | GPR35KDM4EMAPTTP53LMNA | |
| SCHEMBL31634948 | 0.75 | MAOB (0.73) | KDM4EMAOBCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL31619651 | 0.75 | MAOB (0.73) | KDM4EMAOBCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL19744265 | 0.74 | KDM4E (0.47) | GPR35KDM4EMAOBMAPTTP53 | |
| SCHEMBL19744138 | 0.73 | KDM4E (0.52) | GPR35KDM4EMAOBMAPTTP53 | |
| SCHEMBL29540494 | 0.73 | MAOB (0.66) | GPR35KDM4EMAOBCSNK2A2CSNK2B | |
| SCHEMBL22617125 | 0.73 | MAOB (0.66) | GPR35KDM4EMAOBCSNK2A2CSNK2B | |
| SCHEMBL22617244 | 0.72 | MAOB (0.64) | GPR35KDM4EMAOBCSNK2A2CSNK2B | |
| SCHEMBL19743758 | 0.71 | GPR35 (0.59) | GPR35KDM4ECSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641864-B | Anti-infective agents | 邓迪大学 | 2023-04-04 | — | — | CN | disclosed |
| US-11485720-B2 | Anti-infective agents | UNIVERSITY OF DUNDEE (GB) | 2022-11-01 | — | — | US | disclosed |
| EP-3472141-B1 | ANTI-INFECTIVE AGENTS | UNIV DUNDEE (GB) | 2022-10-05 | — | — | EP | disclosed |
| US-20210101877-A1 | ANTI-INFECTIVE AGENTS | UNIVERSITY OF DUNDEE (GB) | 2021-04-08 | — | — | US | disclosed |
| US-20210101877-A1 | ANTI-INFECTIVE AGENTS | UNIVERSITY OF DUNDEE (GB) | 2021-04-08 | — | — | US | disclosed |
| US-20190225592-A1 | ANTI-INFECTIVE AGENTS | UNIVERSITY OF DUNDEE (GB) | 2019-07-25 | — | — | US | disclosed |
| US-20190225592-A1 | ANTI-INFECTIVE AGENTS | UNIVERSITY OF DUNDEE (GB) | 2019-07-25 | — | — | US | disclosed |
| EP-3472141-A1 | ANTI-INFECTIVE AGENTS | University Of Dundee (GB) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017221002-A1 | ANTI-INFECTIVE AGENTS | UNIVERSITY OF DUNDEE (GB) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485720-B2 | Anti-infective agents | C1R, RRS1, ARG1 | GPR35 3114/4885KDM4E 2159/4885MAOB 2696/4885 |
| US-20210101877-A1 | ANTI-INFECTIVE AGENTS | C1R, RRS1, ARG1 | GPR35 3114/4885KDM4E 2159/4885MAOB 2696/4885 |
| US-20190225592-A1 | ANTI-INFECTIVE AGENTS | C1R, ARG1, MSR1 | GPR35 3007/4885KDM4E 2344/4885MAOB 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.